ArrowMark Colorado Holdings’s Apogee Therapeutics APGE Stock Holding History

ArrowMark Colorado Holdings’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.21M	Hold	109,410	–	–	0.24%	124
2025 Q4	$8.26M	Hold	109,410	–	–	0.18%	155
2025 Q3	$4.35M	Hold	109,410	–	–	0.08%	202
2025 Q2	$4.75M	Hold	109,410	–	–	0.09%	189
2025 Q1	$4.09M	Hold	109,410	–	–	0.07%	189
2024 Q4	$4.96M	Hold	109,410	–	–	0.07%	191
2024 Q3	$6.43M	Hold	109,410	–	–	0.08%	168
2024 Q2	$4.31M	Hold	109,410	–	–	0.05%	214
2024 Q1	$7.27M	Buy	109,410 +30,000	+38%	+$1.31M	0.08%	178
2023 Q4	$2.22M	Hold	79,410	–	–	0.02%	236
2023 Q3	$1.69M	Buy	+79,410	New	+$1.75M	0.02%	242

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ArrowMark Colorado Holdings's APGE Position: Q1 2026 in Review

ArrowMark Colorado Holdings held its Apogee Therapeutics (APGE) position steady in Q1 2026 at 109,410 shares worth $9.21M. The position accounts for 0.24% of the portfolio, ranked #124.

ArrowMark Colorado Holdings first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

ArrowMark Colorado Holdings held 109,410 shares of Apogee Therapeutics worth $9.21M as of Q1 2026.
ArrowMark Colorado Holdings left its Apogee Therapeutics share count unchanged in Q1 2026.
Apogee Therapeutics made up 0.24% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #124 holding.
ArrowMark Colorado Holdings first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.